Download of the booklet: Final Program & Keypoints
Friday, January 30, 2026
8.30-8.40 Opening
Heinz Ludwig and Jesús F. San-Miguel
MYELOMA BIOLOGY AND RISK STRATIFICATION
Moderator: Heinz Ludwig
8.40-9.00 The role of genomics in assessing the transformation risk of precursor conditions to multiple myeloma
Niccolò Bolli
9.00-9.20 The role of the immune environment in the evolution and course of myeloma
Leo Rasche
9.20-9.40 New risk classification of multiple myeloma
Anaïs Schavgoulidze
9.40-10.00 Diagnostic workup of monoclonal gammopathies
Kwee Yong
10.00-10.25 Discussion around important questions
• Comparison of genomic with clinical patterns for prediction of risk of progression of MGUS/SMM
• Are there any means to strengthen the immune environment
• Hurdles for the implementation of the new risk classification
• Non-genomic risk classifiers
10.25-10.45 Break
NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT
Moderator: Jesús F. San-Miguel
10.45-11.05 Response assessment – technical and clinical considerations
Bruno Paiva
11.05-11.25 New developments in imaging for diagnosis and prognostication
Elena Zamagni
CLINICAL VARIANTS OF MONOCLONAL GAMMOPATHIES
11.25-11.45 Management of extramedullary myeloma, solitary plasmocytoma and plasma cell leukemia
Meral Beksac
11.45-12.05 Smoldering multiple myeloma: risk assessment and candidates for therapy
Mario Boccadoro
12.05-12.30 Discussion around important questions
• When is a bone marrow biopsy required in MGUS?
• Circulating plasma cells for disease and response assessment
• Optimizing imaging technologies – MRI and PET/CT
• Comparison of different mass spectrometry techniques (MALDI-TOF, clonotypic peptide detection approach)
• Is MRD assessment in MGUS-like MM useful?
12.30-13.30 Lunch
NEW DEVELOPMENTS IN TREATMENT, PART ONE
Moderator: Jesús F. San-Miguel
13.30-13.50 First line therapy of multiple myeloma
Evangelos Terpos
13.50-14.10 Game changing results from recent EMN trials
Pieter Sonneveld
14.10-14.30 Management of high-risk disease
Martin Kaiser
14.30-14.50 How to select treatment after relapse
Maria-Victoria Mateos
14.50-15:15 Discussion around important questions
• Can the prediction of early progression in SMM be further improved?
• Can upfront ASCT be deferred or abandoned in good risk patients in the era of novel quadruplets?
• What is the optimal number of induction and consolidation cycles?
• MRD guided therapy ready for prime time?
• Initiation of therapy at biochemical progression?
15.15-15.35 Break
NEW DEVELOPMENTS IN TREATMENT, PART TWO
Moderator: Heinz Ludwig
15.35-15.55 The impact of frailty and comorbidities on treatment selection
Alessandra Larocca
15.55-16.15 Maintenance treatment
Francesca Gay
16.15-16.35 Prevention of infectious complications of immune therapies
Heinz Ludwig
16.35-17.00 Discussion around important questions
• Treatment of very elderly patients
• How to distinguish between myeloma and patient related comorbidities?
• New concepts for maintenance therapy
• Treatment duration
• Impact of patient risk factors on treatment selection
• Recommendations for Immunoglobulin supplementation
KEYNOTE LECTURE
17.00-17.30 On the road to cure-present achievements and future developments
Jesús F. San-Miguel
Saturday, January 31, 2026
HOT TOPICS IN MYELOMA
Moderator: Jesús F. San-Miguel
8.30-8.50 How to integrate CELMoDs, Selinexor, Melflufen and bcl2 inhibitors in present management
Evangelos Terpos
8.50-9.10 How to optimize the use of bispecific and trispecific antibodies
Niels van de Donk
9.10-9.30 Cellular therapies in MM, current options and ongoing developments
Hermann Einsele
9.30-9.55 Discussion around important questions
• Is there a preferred target for BsAbs and CAR-T cells?
• Pros and cons for BsAbs or CAR-T cells
• Impact of CAR-T cell persistence on outcome
• Prevention of toxicities of BsAbs and CAR-T cells
• Role of ADC, antigen loss, and of soluble BCMA
9.55-10.15 Break
AMYLOIDOSIS, WADENSTRÖM’S DISEASE AND ARTIFICIAL INTELLEGENCE
Moderator: Heinz Ludwig
10.15-10.35 Fixed duration or continuous therapy: Recommendations for specific patient subgroups
Mohamad Mohty
10.35-10.55 Treatment approaches in Waldenström’s disease
Efstathios Kastritis
10.55-11.15 Recent developments Amyloidosis research and therapy
Efstathios Kastritis
11.15-11.35 AI in multiple myeloma
Claudio Cerchione
11.35-12.00 Discussion around important questions
• Is cure a realistic goal in amyloidosis?
• Cellular therapies in amyloidosis
• Treatment of patients failing to first-line treatment with BTK inhibitors and CD20+ based therapies
• Is there a role for anti-BCMA treatments in Waldenström’s disease as 2/3 express BCMA on their tumor clones?
• Limitations of AI in myeloma
12.00-12.10 Closure of the meeting
Heinz Ludwig